Jorge Cortes, MD, Georgia Cancer Center


Future Management of Chronic Myeloid Leukemia

March 2nd 2022

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Monitoring Patients With Chronic Myeloid Leukemia

February 23rd 2022

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Treatment for CML: Dose Adjustment or Discontinuations

February 23rd 2022

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

An Overview of CML Treatment Toxicities

February 16th 2022

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

Chronic Myeloid Leukemia: Asciminib’s Toxicity Profile

February 16th 2022

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

CML Management: Personal Experience With Asciminib

February 9th 2022

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia

February 9th 2022

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

CML: Third-Line Treatment Options for Chronic Myeloid Leukemia

February 2nd 2022

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

CML: Challenges and Unmet Needs in Later-Line Therapy

February 2nd 2022

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

Selecting Second-Line Therapy for Chronic Myeloid Leukemia

January 26th 2022

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

Role of Tyrosine Kinase Inhibitors in Treatment of CML

January 26th 2022

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

Chronic Myeloid Leukemia: Assessing Treatment Response

January 19th 2022

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

Chromosomal Abnormalities and Genetic Alterations in CML

January 19th 2022

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

An Overview of Chronic Myeloid Leukemia (CML)

December 14th 2021

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

July 8th 2021

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

July 8th 2021

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

July 8th 2021

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

July 8th 2021

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.